Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation
|
|
- Shavonne Stafford
- 8 years ago
- Views:
Transcription
1 Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation
2 Sipuleucel-T Manufacturing Process Day 1 Leukapheresis Day 2-3 Sipuleucel-T is manufactured Day 3-4 Patient is infused Apheresis Center Dendreon Doctor s Office COMPLETE COURSE OF THERAPY: 3 CYCLES
3 Cellular Immunotherapy with sipuleucel-t PA224 with resting antigen presenting cell (APC) APC takes up the antigen Antigen is processed and presented on surface of the APC Fully activated, the APC is now sipuleucel-t INFUSE PATIENT Active T-cell Inactive T-cell T-cells proliferate and attack cancer cells Sipuleucel-T activates T-cells in the body The precise mechanism of sipuleucel-t in prostate cancer has not been established.
4 Antigen Presentation Assay (Hybridoma Assay) Mouse T Cell Hybridoma (Papillon, Paperino) TCR CD4 IL-2 PAP Peptide HLA DR-1 Human Antigen Presenting Cell (Sipuleucel-T)
5 Challenges for Autologous Cellular Immunotherapy Product Potency Testing Challenges Heterogeneous and limited final product Introduce assay variability No reference material HLA-restricted APC activity Varied patient HLA haplotypes Short product shelf life Long bioassay incubation time Solutions Surrogate potency assay Identify target cells responsible for antigen presentation to T cells Correlate target cell phenotype and antigen presentation activity Develop assays that can be used for product potency test Reproducible, robust Universal to all patient Short incubation time Tracking assay over time Confirm potency data with clinical outcome.
6 Antigen Presentation Tracks with PA224-FITC Uptake Tritiated thymidine uptake (cpm) 3, 25, 2, 15, 1, 5, FITC +ve FITC -ve Papillon 7, 6, 5, 4, 3, 2, 1, Paperino No. of input cells
7 PA224-FITC is Taken Up by CD54+ APCs CD54 HLA-DR CD4 PA224-FITC CD3 CD19 CD14 PA224-FITC
8 Antigen Presentation Activity Tracks with CD54+ Cells Tritiated thymidine uptake (cpm) 25, 2, 15, 1, 5, CD54 +ve CD54 -ve Papillon 5, 4, 3, 2, 1, Paperino No. of input cells
9 Upregulation of Co-stimulatory Molecules on APCs Pre-culture Post-culture CD54 5, 4, 3, 2, CD56 1, CD4 HLA-DR
10 Surrogate Potency Assays Quantity of APC Total number of CD54+ cells Measured by flow cytometry and total nucleated cell count Quality of APC CD54 up-regulation Measured CD54 expression by flow cytometry before/after culture with PA224 antigen
11 CD54 Up-regulation Ratio Before Culture After Culture CD54(+) A BDS65.7 Large CD54 + Cells IgG2b + Cells A FP-Control.7 Large CD54 + Cells IgG2b + Cells FSC-Height A BDS FSC-Height A FP-Control.7 File: A BDS65.7 Sample ID: Patient ID: Acquisition Date: 5-Jun Gate: G4 CD54 PE Events Geo Mean File: A FP-Control.7 Sample ID: Patient ID: Acquisition Date: 7-Jun-6 Gate: 1 G CD54 PE Events Geo Mean
12 Potency Assay Overview Flow based assays to quantify total CD54+ cells and changes in CD54 expression before and after incubation Not limited by HLA haplotypes Short assay incubation time Reproducible and robust Commercially available fluorescence standard
13 Antigen Presentation Decays under a Stressed Condition Normal Storage Stressed Condition 12% 1% RAPA Decay A2-345 A A % 1% RAPA Decay A A A % of Time 8% 6% 4% % of Time 8% 6% 4% 2% 2% % Time % Time
14 Total Number of CD54+ Cells Decays under a Stressed Condition Normal Storage Stressed Condition 12% 1% Total CD54+ cells Decay A2-345 A A % 1% Total CD54+ Cell Decay A A A % of Time 8% 6% 4% % of Time 8% 6% 4% 2% 2% % % Time Time
15 CD54 Expression Decays under a Stressed Condition Normal Storage Stressed Condition 12% CD54 Expression Decay A2-345 A A % CD54 Expression Decay A A A % 1% % of Time 8% 6% 4% % of Time 8% 6% 4% 2% 2% % % Time Time
16 K-M Survival Curves: Cumulative CD54 Cell Dose Above vs. Below the Median Comparison sipuleucel-t ( 2.3 x 1 9 cells; n=73) Percent survival sipuleucel-t (< 2.3 x 1 9 cells; n=73) p=.237 Placebo (n=76) Survival Time (months)
17 K-M Survival Curves: Cumulative CD54 Up-regulation Above vs. Below the Median Comparison Percent survival sipuleucel-t ( 22.3; n=73) sipuleucel-t(< 22.3; n=73) p=.6 Placebo (n=76) Survival Time (months)
18 Conclusions PAP-specific HLA DRβ1-restricted T cell hybridoma demonstrates antigen presentation activity in sipuleucel-t cells. PAP-specific antigen presentation activity resides with CD54+ cells. CD54 up-regulation and total CD54+cells are biologically relevant potency measures. Antigen presentation and CD54 up-regulation assays can be stability indication assays. CD54 up-regulation may correlate with survival.
19
20 Overview Sipuleucel-T: Investigational active immunotherapy for prostate cancer Potency assay challenges for autologous cellular products Model system: Antigen presentation assay Surrogate markers Correlating antigen presentation and other biological activity Tracking potency assay Confirmation: Comparing potency assay with clinical outcome
21 Correlation: CD54 and CD14 in Final Product Healthy Donors and Clinical Trial Patients 25 FP CD14 y =.9321x R 2 = B - FP CD14 y =.8531x R 2 =.8323 Healthy Donor D992B Linear (HD) Linear (D992B) 2 CD14 Cell Count CD54 Cell Count
22 Antigen Presentation Dose Response Curve OD Log1(FP/mL) Reference Test
23 Relative Antigen Presentation Activity (RAPA) Log1(OD) Log1(FP/mL) Reference Test Fitted Ref Fitted Test
24 Antigen Presentation to T Cells T-cell CD154 CD11/CD18 TCR CD8 CD4 CD28 Peptide CD4 CD54 MHC class I MHC class II CD8 CD86 Antigen Presenting Cell
25 Assay Characterization %CD54 cells # of CD54 molecules Intra-assay precision <7% <4% Inter-assay precision <6.5% <13.5% Lab-to-Lab variability <2% <9%
26 Fluorescence Standard < 7 Med - High High Med - Low Low File: /4/99.1 X Parameter: FL2-H CD54 PE 1:1 (Log) Marker Events Geo Mean CV All Low Med - Low Med - High High > 7 Calibration curve Slope: Intercept: # PE molecules per bead # PE molecules Geometric means per bead of bead peaks
International Beryllium Conference, Montreal, Canada March 10, 2005
Alternative Lymphocyte Proliferation Tests: BrdU and Flow Cytometry Based Tests International Beryllium Conference, Montreal, Canada March 10, 2005 Tim K. Takaro Department of Environmental and Occupational
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationBioinformatics for cancer immunology and immunotherapy
Bioinformatics for cancer immunology and immunotherapy Zlatko Trajanoski Biocenter, Division for Bioinformatics Innsbruck Medical University Innrain 80, 6020 Innsbruck, Austria Email: zlatko.trajanoski@i-med.ac.at
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationImmuno-Oncology Model Application in the Preclinical Treatment Setting
Immuno-Oncology Model Application in the Preclinical Treatment Setting Maryland Franklin, Ph.D. Senior Director, Scientific Development mfranklin@molecularimaging.com July 22, 2015 Tumor Models Conference
More informationStepcount. Product Description: Closed transparent tubes with a metal screen, including a white matrix at the bottom. Cat. Reference: STP-25T
Product Description: Closed transparent tubes with a metal screen, including a white matrix at the bottom Cat. Reference: STP-25T Reagent provided:: 25 Stepcount tubes for 25 test INTENDED USE. Immunostep
More informationT Cell Immunotherapy for Cancer
T Cell Immunotherapy for Cancer Chimeric Antigen Receptors Targeting Tag-72 Glycoprotein for Colorectal Cancer Mitchell H. Finer Ph.D Genetix Pharmaceuticals Inc Work Completed at Cell Genesys Inc T Cell
More informationFluorescence Compensation. Jennifer Wilshire, PhD jennifer@flowjo.com
Fluorescence Compensation Jennifer Wilshire, PhD jennifer@flowjo.com Outline 1. Compensation Basics 2. Practical Applications -selecting comp controls (cells, stains?) 3. Multicolor Issues -spreading due
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationStandardization, Calibration and Quality Control
Standardization, Calibration and Quality Control Ian Storie Flow cytometry has become an essential tool in the research and clinical diagnostic laboratory. The range of available flow-based diagnostic
More informationHemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy
HemaCare Corporation Company Overview Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy 2015 HemaCare Corporation Leading provider of apheresis products, human blood cells,
More informationSuppl. Figure 1. Cells cultured in oxldl take up Oil Red O in a time-dependent
Suppl. Figure 1. Cells cultured in oxldl take up Oil Red O in a time-dependent manner. Uptake of Oil Red O was performed as detailed in Materials and Methods and absorbance of samples was expressed as
More informationMulticolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility
Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility The mention of commercial products, their sources, or their use in connection
More informationSTANDARD OPERATING PROCEDURE
Title: Lymphocyte Proliferation Assay (LPA) Using 3 H- Thymidine Incorporation Assay Core Name: Lloyd Mayer, Mount Sinai Medical Center Effective Date: 02/16/2012 Trial Number: ITN047AI SOP # ITN2800 SOP
More informationSpherotech, Inc. 27845 Irma Lee Circle, Unit 101, Lake Forest, Illinois 60045 1
78 Irma Lee Circle, Unit 0, Lake Forest, Illinois 00 SPHERO TM Technical Note STN- Rev B 008 DETERMINING PMT LINEARITY IN FLOW CYTOMETERS USING THE SPHERO TM PMT QUALITY CONTROL EXCEL TEMPLATE Introduction
More informationT Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationCancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview
Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:
More information低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD
CNIC-01513 PUTH-0001 低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD 中 国 核 情 报 中 心 China Nuclear Information
More informationModelling and analysis of T-cell epitope screening data.
Modelling and analysis of T-cell epitope screening data. Tim Beißbarth 2, Jason A. Tye-Din 1, Gordon K. Smyth 1, Robert P. Anderson 1 and Terence P. Speed 1 1 WEHI, 1G Royal Parade, Parkville, VIC 3050,
More informationUsing the BD TM Cytometer Setup and Tracking (CS&T) System for Instrument Characterization and Performance Tracking
Using the BD TM Cytometer Setup and Tracking (CS&T) System for Instrument Characterization and Performance Tracking Mark KuKuruga Senior Technical Applications Specialist BD Biosciences 23-14462-00 Outline
More informationIntroduction to flow cytometry
Introduction to flow cytometry Flow cytometry is a popular laser-based technology. Discover more with our introduction to flow cytometry. Flow cytometry is now a widely used method for analyzing the expression
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies
ISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies Fouad Atouf, Ph.D. Senior Scientific Liaison Biologics
More informationTERUMO Corporation Business Strategy Conference
TERUMO Corporation Business Strategy Conference THERAPEUTIC SYSTEMS & CELL PROCESSING MARK FLOWER GLOBAL MARKETING December 5, 2011 Regenerative Medicine, Cell Therapy, & Cell Processing Regenerative Medicine
More informationThe Costimulatory Molecule CD27 Maintains Clonally
Immunity, Volume 35 Supplemental Information The Costimulatory Molecule CD7 Maintains Clonally Diverse CD8 + T Cell Responses of Low Antigen Affinity to Protect against Viral Variants Klaas P.J.M. van
More informationCD34 numeration through the French external quality control: Impact in the implementation of new technical chapters at the European Pharmacopoeia
CD34 numeration through the French external quality control: Impact in the implementation of new technical chapters at the European Pharmacopoeia Panterne Béatrice Cells and Tissues Coordinator Batch release
More informationApplying Statistics Recommended by Regulatory Documents
Applying Statistics Recommended by Regulatory Documents Steven Walfish President, Statistical Outsourcing Services steven@statisticaloutsourcingservices.com 301-325 325-31293129 About the Speaker Mr. Steven
More informationCarboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory
Immunology and Cell Biology (1999) 77, 559 564 Special Feature Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory DA FULCHER
More informationDendritic Cells: A Basic Review *last updated May 2003
*last updated May 2003 Prepared by: Eric Wieder, PhD MD Anderson Cancer Center Houston, TX USA What is a dendritic cell? Dendritic cells are antigen-presenting cells (APCs) which play a critical role in
More informationDiane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh
Production Records & Documentation Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh Production Records This Session: Production Records Basic Elements Regulatory
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationMilano Cord Blood Bank 18 year report on cord blood banking and transplant
Milano Cord Blood Bank 18 year report on cord blood banking and transplant Paolo Rebulla, MD Milano Cord Blood Bank Center of Transfusion Medicine, Cellular Therapy and Cryobiology Department of Regenerative
More informationEngineered T cells. Function (growth factor / effector cytokine / effector molecules) Trafficking chemokine receptors
Cell Processing Related Issues: Adoptive T cell Immunotherapy Bernard A. Fox Lab of Molecular and Tumor Immunology Robert W. Franz Cancer Research Center Providence Cancer Center Earle A. Chiles Research
More informationDeep profiling of multitube flow cytometry data Supplemental information
Deep profiling of multitube flow cytometry data Supplemental information Kieran O Neill et al December 19, 2014 1 Table S1: Markers in simulated multitube data. The data was split into three tubes, each
More informationUsing BD FACSDiva CST To. Evaluate Cytometer Performance, Create Custom Assay Settings. and
Using BD FACSDiva CST To Evaluate Cytometer Performance, Create Custom Assay Settings and Implement Cross-Instrument and Cross-Site Standardization of Assays PART 2 Alan M. Stall Director, Advanced Cytometry
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationDefining Response in Prostate Cancer Immunotherapy. Lawrence Fong! University of California, San Francisco!
Defining Response in Prostate Cancer Immunotherapy Lawrence Fong! University of California, San Francisco! U!C! S!F! Prostate Cancer Clinical States Pre-chemotherapy Post-chemotherapy (Scher et al, JCO
More informationAccelerating Antibody Drug Development Using Novel ADCC Reporter Bioassays. Terry Surowy, PhD Research Manager
Accelerating Antibody Drug Development Using Novel ADCC Reporter Bioassays Terry Surowy, PhD Research Manager Outline Antibody drugs and mechanisms of action (MOA) Introduction to ADCC and ADCC Reporter
More informationPhone: 1-877-336-3736 Fax: 1-877-556-3737 M F 8:00 am 9:00 pm ET
QUICK REFERENCE CODING & BILLING GUIDE PHYSICIAN OFFICE CMS National Coverage Determination and Q-Code for PROVENGE Simplifies patient coverage criteria Clarifies coding requirements Expedites electronic
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): November 25, 2014 Effective Date: February 1, 2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationImmunophenotyping peripheral blood cells
IMMUNOPHENOTYPING Attune Accoustic Focusing Cytometer Immunophenotyping peripheral blood cells A no-lyse, no-wash, no cell loss method for immunophenotyping nucleated peripheral blood cells using the Attune
More informationImmunotherapy for Multiple Myeloma. Sarah Holstein, MD, PhD April 2, 2015 MIR-508
Immunotherapy for Multiple Myeloma Sarah Holstein, MD, PhD April 2, 2015 MIR-508 Outline Myeloma overview IMiDs Monoclonal antibodies Anti-CS1 Vaccines Dendritic cell/myeloma fusion Multiple Myeloma Monoclonal
More informationMedigene Corporate Presentation
Medigene Corporate Presentation This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing
More informationTechnical Bulletin. Standardizing Application Setup Across Multiple Flow Cytometers Using BD FACSDiva Version 6 Software. Abstract
arch 212 Standardizing Application Setup Across ultiple Flow Cytometers Using BD FACSDiva Version 6 Ellen einelt, ervi Reunanen, ark Edinger, aria Jaimes, Alan Stall, Dennis Sasaki, Joe Trotter Contents
More informationApplication Information Bulletin: Set-Up of the CytoFLEX Set-Up of the CytoFLEX* for Extracellular Vesicle Measurement
Application Information Bulletin: Set-Up of the CytoFLEX Set-Up of the CytoFLEX* for Extracellular Vesicle Measurement Andreas Spittler, MD, Associate Professor for Pathophysiology, Medical University
More informationFDA Perspective on the Regulation of TCR/CAR T-cell Products
FDA Perspective on the Regulation of TCR/CAR T-cell Products Raj K. Puri, M.D., Ph.D. Director, Division of Cellular and Gene Therapies, FDA, CBER CIMT2014 Talk (by Phone) Date: May 8, 2014 Time: 12:30
More informationA Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy
International Journal of Modeling Optimization, Vol 5, No 3, June 2015 A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy Dwi Lestari Ratnasari Dwi Ambarwati Abstract This
More informationIdentification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
More informationChapter 10. Summary & Future perspectives
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
More informationBD FACSComp Software Tutorial
BD FACSComp Software Tutorial This tutorial guides you through a BD FACSComp software lyse/no-wash assay setup run. If you are already familiar with previous versions of BD FACSComp software on Mac OS
More informationAssays to evaluate cell-mediated immunity. Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands
Assays to evaluate cell-mediated immunity Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands CBER/NIAID/WHO, Bethesda MD, December 11 2007 A working model of an antiviral
More informationSEARCHING FOR A BONE MARROW DONOR
SEARCHING FOR A BONE MARROW DONOR Angela received a bone marrow transplant from an unrelated donor to treat her non-hodgkin s lymphoma. INFORMATION FOR PATIENTS AND THEIR FAMILIES For patients who need
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationSpecialty Lab and Immunological Testing Services
Specialty Lab and Immunological Testing Services OVER 30 YEARS OF SPECIALTY LAB EXPERIENCE Precision for Medicine recognizes the critical role that sample testing and handling play in achieving high-quality,
More informationCMC Writing for IND Applications. David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop
CMC Writing for IND Applications David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop CMC Writing for IND Applications ~Outline~ What is the CMC section? Who writes the CMC section?
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More information1++ 47.00 0.1+ 104.00 5++ 26.00 1+ 484.00 10++ 20.00 2+ 363.00 20++ 15.25 5+ 244.00 50++ 10.15 10+ 183.00 100++ 7.60 500++ 4.15
Since April 1991, the International Blood Group Reference Laboratory (IBGRL) has had a range of monoclonal antibodies for immunohaematological research marketed under the name "IBGRL Research Products".
More informationEnhancing Anti-Tumor Activity of Checkpoint Inhibition
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
More informationChimeric Antigen Receptor T Cell Therapy
Chimeric Antigen Receptor T Cell Therapy Yi Lin, MD, PhD Mayo Clinic, Rochester, MN Alliance Spring Group Meeting - May 13, 2016 Presentation Objectives l Scientific overview of chimeric antigen receptor
More information123count ebeads Catalog Number: 01-1234 Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use.
Page 1 of 1 Catalog Number: 01-1234 Also known as: Absolute cell count beads GPR: General Purpose Reagents. For Laboratory Use. Normal human peripheral blood was stained with Anti- Human CD45 PE (cat.
More informationFighting the Battles: Conducting a Clinical Assay
Fighting the Battles: Conducting a Clinical Assay 6 Vocabulary: In Vitro: studies in biology that are conducted using components of an organism that have been isolated from their usual biological surroundings
More informationLikelihood Approaches for Trial Designs in Early Phase Oncology
Likelihood Approaches for Trial Designs in Early Phase Oncology Clinical Trials Elizabeth Garrett-Mayer, PhD Cody Chiuzan, PhD Hollings Cancer Center Department of Public Health Sciences Medical University
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationInstrument Characterization and Performance Tracking for Digital Flow Cytometers
Instrument Characterization and Performance Tracking for Digital Flow Cytometers BD Biosciences Cytometer Set-up & Tracking (CS&T) System For Research Use Only. Not for use in diagnostic or therapeutic
More informationHow To Collect A Leukapheresis Collection
Leukapheresis Collection Insights in Unstimulated Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving a Combination of Autologous Immunotherapy (AGS-003) and Sunitinib: From the Ongoing
More informationwww.gbo.com/bioscience Tissue Culture 1 Cell/ Microplates 2 HTS- 3 Immunology/ HLA 4 Microbiology/ Bacteriology Purpose Beakers 5 Tubes/Multi-
11 Cryo 5 Tubes/Multi 2 HTS 3 Immunology / Immunology Technical Information 3 I 2 96 Well ELISA 3 I 4 96 Well ELISA Strip Plates 3 I 6 8 Well Strip Plates 3 I 7 12 Well Strip Plates 3 I 8 16 Well Strip
More informationThree Rules for Compensation Controls
From FlowJo s Daily Dongle Three Rules for Compensation Controls First and foremost, there must be a single-stained control for every parameter in the experiment! In addition, there are three rules for
More informationScientific Challenges for Development of Biosimilar Monoclonal Antibodies. Rafiqul Islam Director, Global Bioanalytical Services Celerion
Scientific Challenges for Development of Biosimilar Monoclonal Antibodies Rafiqul Islam Director, Global Bioanalytical Services Celerion Presentation outline Biosimilars Definitions and Concepts Regulatory
More informationCELL CYCLE BASICS. G0/1 = 1X S Phase G2/M = 2X DYE FLUORESCENCE
CELL CYCLE BASICS Analysis of a population of cells replication state can be achieved by fluorescence labeling of the nuclei of cells in suspension and then analyzing the fluorescence properties of each
More informationThe validation of a tumour control probability (TCP) model for supporting radiotherapy treatment planning.
The validation of a tumour control probability (TCP) model for supporting radiotherapy treatment planning. KAROLINA KOKUREWICZ S U P E R V I S O R S : D I N O J A R O S Z Y N S K I, G I U S E P P E S C
More informationHead of College Scholars List Scheme. Summer Studentship. Report Form
Head of College Scholars List Scheme Summer Studentship Report Form This report should be completed by the student with his/her project supervisor. It should summarise the work undertaken during the project
More informationImmunophenotyping Flow Cytometry Tutorial. Contents. Experimental Requirements...1. Data Storage...2. Voltage Adjustments...3. Compensation...
Immunophenotyping Flow Cytometry Tutorial Contents Experimental Requirements...1 Data Storage...2 Voltage Adjustments...3 Compensation...5 Experimental Requirements For immunophenotyping with FITC and
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationAnalytical Test Method Validation Report Template
Analytical Test Method Validation Report Template 1. Purpose The purpose of this Validation Summary Report is to summarize the finding of the validation of test method Determination of, following Validation
More informationFlow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.
Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy. At the end of this session, the participant will be able to: 1. Describe the components of a flow cytometer 2. Describe the gating
More informationStatistics and Pharmacokinetics in Clinical Pharmacology Studies
Paper ST03 Statistics and Pharmacokinetics in Clinical Pharmacology Studies ABSTRACT Amy Newlands, GlaxoSmithKline, Greenford UK The aim of this presentation is to show how we use statistics and pharmacokinetics
More informationImmunodiagnostyka w rozrostach układu krwiotwórczego - rola cytometrii przepływowej
Immunodiagnostyka w rozrostach układu krwiotwórczego - rola cytometrii przepływowej Antygeny komórkowe Sensory Metabolic Adhesion Flow Cell Injector Tip Fluorescence signals Focused laser beam Sheath fluid
More informationAPPLICATION INFORMATION
DRAFT: Rev. D A-2045A APPLICATION INFORMATION Flow Cytometry 3-COLOR COMPENSATION Raquel Cabana,* Mark Cheetham, Jay Enten, Yong Song, Michael Thomas,* and Brendan S. Yee Beckman Coulter, Inc., Miami FL
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationSuperior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes
Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes Outlines Brief introduction of OriGene s mission on gene-centric product solution. TrueMAB monoclonal antibody
More informationMultiQuant Software 2.0 for Targeted Protein / Peptide Quantification
MultiQuant Software 2.0 for Targeted Protein / Peptide Quantification Gold Standard for Quantitative Data Processing Because of the sensitivity, selectivity, speed and throughput at which MRM assays can
More informationELITE Custom Antibody Services
ELITE Custom Antibody Services ELITE Custom Antibody Services Experience, confidence, and understanding As a manufacturer and service provider, we have the experience, confidence, and understanding to
More informationTITLE: TRU-COUNT ENUMERATION OF T-CELLS IN WHOLE
TITLE: TRU-COUNT ENUMERATION OF T-CELLS IN WHOLE PRINCIPLES OF THE PROCEDURE: When whole blood is added to the reagent, the fluorochrome labeled antibodies in the reagent bind specifically to leukocyte
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationIdentification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans
Identification of Tick-Borne Encephalitis Virus CD4+ and CD8+ T-Cell Epitopes in Vaccinated or Naturally Infected Humans Schwaiger Julia Clinical Institute of Virology 29.06.2009 1 Thank you! Franz X.
More informationMouse IFN-gamma ELISpot Kit
Page 1 of 8 Mouse IFN-gamma ELISpot Kit Without Plates With Plates With Sterile Plates Quantity Catalog Nos. 862.031.001 862.031.001P 862.031.001S 1 x 96 tests 862.031.005 862.031.005P 862.031.005S 5 x
More informationCD34+ CD45- Cells Isolated from Human Blood Have Molecular and Functional Characteristics of Vascular Endothelial Progenitors
CD34+ CD45- Cells Isolated from Human Blood Have Molecular and Functional Characteristics of Vascular Endothelial Progenitors Yajuan Jiang 1, Alexander M. Tsankov 2, Alexander Meissner 2 and David W. O
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationThe Journal of Experimental Medicine
Supplemental Material Haines et al., http://www.jem.org/cgi/content/full/jem.20080996/dc1 The Journal of Experimental Medicine Subcloning of murine PTK7 cdna segments into pegfp-n3 and CHO cell transfection.
More information